Clinical Trials
18 trialsNCT04534205 2026-05-22
AHEAD-MERIT
BioNTech SE
Phase 2/3 Recruiting
NCT06989437 2026-05-20
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer
Phase 2/3 Recruiting
NCT06697301 2026-05-08
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Eikon Therapeutics
Phase 2/3 Recruiting
NCT06943755 2026-04-17
STELLAR-311
Exelixis
Phase 2/3 Recruiting
NCT06947928 2026-04-17
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
Phase 2/3 Recruiting
NCT06506955 2026-04-03
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
NCT06581406 2026-04-02
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune, Inc.
Phase 2/3 Recruiting
NCT07321847 2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3 Not yet recruiting
NCT06719479 2024-12-05
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
SUNHO(China)BioPharmaceutical CO., Ltd.
Phase 2/3 Not yet recruiting
NCT03512756 2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc
Phase 2/3 Terminated
NCT02186301 2019-05-07
EGFR
Clovis Oncology, Inc.
Phase 2/3 Terminated
NCT01572727 2017-03-09
BELLE-4
Novartis
Phase 2/3 Completed
NCT00389155 2015-12-07
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Bristol-Myers Squibb
Phase 2/3 Completed
NCT00561990 2015-10-15
Nimotuzumab in Adults With Pancreatic Cancer
Oncoscience AG
Phase 2/3 Completed
NCT00401323 2011-01-20
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sanofi
Phase 2/3 Completed
NCT00290953 2008-12-23
SESAME
Sanofi
Phase 2/3 Completed
NCT00035334 2006-02-14
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Bellus Health Inc. - a GSK company
Phase 2/3 Completed
NCT00055562 2005-06-24
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Celgene
Phase 2/3 Completed